Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
There were no differences in OS among patients with NPM1-mutated myeloid neoplasms with varying bone marrow blasts.
Azacitidine plus quizartinib achieved a high ORR and a promising safety profile in patients with FLT3-Mutated MDS.
Two clinical experts offer detailed guidance on how to use iron chelation therapy in MDS care.
Multivariable analysis in a phase II study linked the supplements to an overall survival benefit in patients.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Elias Jabbour, MD, gives MDS highlights from EHA 2024.
Advertisement
Compared with epoetin alfa, luspatercept more frequently yielded improvements in anemia measures in lower-risk MDS.
A phase II study evaluated a combination of the IMM01 fusion protein with azacitidine in untreated MDS.
Achieving complete cytogenetic response results in the best overall survival in patients with MDS with abnormal cytogenetics.
A database analysis compares how much time patients spend in healthcare settings, based on receiving oral, IV, or SC HMAs.
The authors reported clinically meaningful responses of luspatercept treatment from patients enrolled in the COMMANDS trial.
ESA treatment after red blood cell transfusions was associated with worse survival compared with ESAs prior to transfusions.
The approval was based on efficacy and safety results of the randomized, placebo-controlled IMerge study.
Dr. Garcia-Manero discussed the phase II ASTREON trial on myelodysplastic syndromes at the 2024 ASCO Annual Meeting.
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.